|
Hyderabad: US-based
global medical device company St. Jude Medical Inc. will make its
latest technologies available to patients in India, a top company
official said here.
"We will continue to launch patient-benefitting technologies as
well as to invest in our employees, physician-training and
important clinical research that helps advance the practice of
medicine in India," Kaustav Banerjee, country manager, St. Jude
Medical, told IANS.
St. Jude manufactures and distributes cardiovascular medical
devices for the cardiac rhythm management, cardiology and cardiac
surgery and atrial fibrillation therapy areas and neurostimulation
medical devices for the management of chronic pain.
Banerjee said India is a focus market for the company, which
Fortune magazine recently ranked as the top admired company in the
medical equipment category, and among the top 50 most admired in
the world.
"India is a very important market for St. Jude Medical and we are
dedicated to improving the care of patients throughout the
country," he said.
The firm, which has its India headquarters in Hyderabad, is
focussing on educating physicians and patients about the symptoms
and potential treatment options for cardiac problems such as
arrhythmia, heart failure, sudden cardiac arrest, and heart valve
repair and replacements.
"From our founding we have established several industry firsts,
including the bi-leaflet heart valve which today remains the
industry gold standard. We have several thousand non-expired
patents in the US and international markets," said Banerjee.
St. Jude Medical is the only company to develop and offer
Quadripolar technology which helps treat patients with heart
failure, offering unique benefits that help the heart beat in sync
that are not found in other cardiac resynchronization therapy
defibrillators (CRT-Ds).
Approximately 10 percent of patients experience pacing-related
lead complications and about five percent require surgical
revision; because the quadripolar technology allows physicians to
non-invasively adjust pacing locations or configurations, it has
the potential to reduce patients' risk of needing multiple
surgeries.
According to Banerjee, the company's Percutaneous coronary
intervention (PCI) optimization technologies, including Fractional
Flow Reserve (FFR) measurement, are changing the way
cardiovascular disease is being treated.
As more people are diagnosed with the disease and healthcare costs
escalate, it has become increasingly important to find treatment
options that can improve patient care in a cost effective manner;
the landmark FAME study FFR has been demonstrated to do just that.
FFR works by providing a physiological measurement that identifies
which coronary narrowings are responsible for obstructing the flow
of blood to a patient's heart muscle. Knowing this measurement
helps physicians to determine the best course of action for his or
her patient, Banerjee added.
Headquartered in St. Paul, Minnesota, and listed on the New York
Stock Exchange, St. Jude sells its devices in more than 100
countries. In 2011, the company's net sales were $5.612 billion.
(Mohammed
Shafeeq can be contacted at m.shafeeq@ians.in)
|
Comments
|
Quick links